{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:42:47Z","timestamp":1787236967469,"version":"build-2736575974"},"reference-count":62,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Intern AIDS Soc"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rifabutin, a rifamycin of equivalent potency to rifampicin, has several advantages in its pharmacokinetic and toxicity profile, particularly in HIV co\u2010infected patients on combined antiretroviral therapy (cART). In this commentary, we evaluate evidence supporting increased global use of rifabutin and highlight key recommendations for action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although extrapolation of data from HIV uninfected patients would suggest non\u2010inferiority, there has been no randomized controlled study comparing rifabutin versus rifampicin in the outcomes of relapse\u2010free cure, in drug susceptible tuberculosis (TB), in HIV co\u2010infected patients on currently utilized cART regimens or in paediatric populations. An important advantage of rifabutin is that compared to the dose adjustments required with rifampicin, it can be co\u2010administered with the integrase strand transfer inhibitors raltegravir or dolutegravir without the need for dose adjustments. This strategy would be easier to implement in a programmatic setting and would save costs. We have assessed cost incentives to utilize rifabutin and have estimated generic costs for a range of rifabutin dosage scenarios. Where facilities are present for drug re\u2010challenge and monitoring for drug toxicity and cross\u2010reactivity, rifabutin offers a switch alternative for adverse drug reactions (ADR)s attributed to rifampicin. This would negate the need to prolong treatment in the absence of a rifamycin as part of short\u2010course multidrug therapy. There is evidence of incomplete cross\u2010resistance to rifampicin and rifabutin. Rifabutin may be useful in rifampicin\u2010resistant TB, in an estimated 20% of cases, based on phenotypic or genotypic rifabutin susceptibility testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rifabutin should be available globally as a first\u2010line rifamycin in HIV co\u2010infected individuals and as a switch option in cases of rifampicin associated ADRs. Further studies are needed to ascertain the utility of rifabutin in rifampicin\u2010resistant rifabutin\u2010susceptible TB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.25333","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T06:40:11Z","timestamp":1563432011000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Global access of rifabutin for the treatment of tuberculosis \u2013 why should we prioritize this?"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-1394","authenticated-orcid":false,"given":"Neesha","family":"Rockwood","sequence":"first","affiliation":[{"name":"Department of Medicine Imperial College London London UK"},{"name":"Department of HIV Medicine Chelsea and Westminster Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Cerrone","sequence":"additional","affiliation":[{"name":"Department of Medicine Imperial College London London UK"},{"name":"Department of HIV Medicine Chelsea and Westminster Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barber","sequence":"additional","affiliation":[{"name":"Department of Global Health and Population Harvard TH Chan School of Public Health Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics Liverpool University Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-5323","authenticated-orcid":false,"given":"Anton L","family":"Pozniak","sequence":"additional","affiliation":[{"name":"Department of HIV Medicine Chelsea and Westminster Hospital London UK"},{"name":"Department of Clinical Research London School of Tropical Medicine and Hygiene London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"9","key":"e_1_2_10_2_1","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison DA","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_1.S15"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010375959"},{"key":"e_1_2_10_7_1","first-page":"CD005159","article-title":"Rifabutin for treating pulmonary tuberculosis","volume":"4","author":"Davies G","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8479(05)80007-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu674"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/381675"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200503-417OC"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/430377"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/598336"},{"issue":"10","key":"e_1_2_10_14_1","first-page":"214","article-title":"Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin\u2010based regimens","volume":"51","author":"Centers for Disease Control, Prevention","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/429321"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.152"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz256"},{"key":"e_1_2_10_18_1","unstructured":"US Department of Health and Human Services NIoH National Cancer Institute.Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.2016[cited 2018 sep 1]. Available from:https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/27\/tb-hiv"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70711-X"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30036-2"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/496980"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0626"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000376"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282faa71e"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv470"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.631"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0390"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608083350604"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912765"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(94)90079-5"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/517366"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw024"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt446"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0068"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw130"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23622"},{"issue":"11","key":"e_1_2_10_38_1","first-page":"1043","article-title":"Tolerability of twice\u2010weekly rifabutin\u2010isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV\u2010infected subjects: a pilot study","volume":"3","author":"Matteelli A","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt150"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky248"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-13"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.10.021"},{"issue":"6","key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1183\/09031936.93.05060680","article-title":"Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection)","volume":"5","author":"Pretet S","year":"1992","journal-title":"Eur Respir J"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.10.013"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0660"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky490"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00855-17"},{"key":"e_1_2_10_48_1","unstructured":"Stop TB Partnership.GDF products list 2018. [cited 2018 sep 1]. Available from:http:\/\/www.stoptb.org\/gdf\/drugsupply\/pc3.asp?PID=897"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2017-000571"},{"issue":"4","key":"e_1_2_10_50_1","first-page":"1243","article-title":"Estimated generic prices for novel treatments for drug\u2010resistant tuberculosis","volume":"72","author":"Gotham D","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_10_51_1","unstructured":"Gilead Sciences.Biktarvy [package insert] Foster City CA. 2018 [cited 2018 sep 1]. Available from:https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf?la=en"},{"key":"e_1_2_10_52_1","unstructured":"RamanathanSW WangH StondellT ChengA KearneyBP.Pharmacokinetics and drug interaction profile of cobicistat boosted\u2010elvitegravir with atazanavir rosuvastatin or rifabutin. 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 16\u201018 2012 Barcelona Spain(abstract O_032012)."},{"key":"e_1_2_10_53_1","unstructured":"Liverpool HIV Pharmacology Group.Liverpool HIV interactions. [cited 2018 sep 1]. Available from:https:\/\/www.hiv-druginteractions.org\/"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt421"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz068"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00917.x"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01947"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30433-7"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.4.380"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00652-12"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-010-0057-5"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.5.621"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01768"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjia2.25333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.25333","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T20:56:36Z","timestamp":1694206596000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1002\/jia2.25333"],"URL":"https:\/\/doi.org\/10.1002\/jia2.25333","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2018-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e25333"}}